UFPT Posts Q3 Results as Shorts Keep Retreating

UFP Technologies has now reported Q3 results, and the stock's first reaction is a modest further decline, leaving the question of whether the bear thesis that accumulated through the summer still has legs.

The stock fell 1.3% on the day of the note to $280.32, extending a 4.9% loss on the week and 6.8% over the past month. That drift lower came into the print and has continued after it. The Q3 earnings history is thin on reaction data, though the one prior release with a recorded outcome, October 30, saw the stock drop 3.2% the following day. The pattern so far in this earnings cycle is consistent with that prior move.

Short positioning has continued the gradual retreat described in Tuesday's earnings preview. Bears have cut exposure by roughly 10% over the past month, with short interest now at 12.5% of the free float, down from above 14% in early October. The direction of travel is unambiguous. Yet the absolute level remains elevated for a mid-cap health care supplies name, and the ORTEX short score of 71.4 still ranks in the bottom 5th percentile of the broader universe, one of the more scrutinised stocks in the market by that measure. Availability has loosened compared with the week prior, now running at 172%, meaning there are more than 1.7 shares available to borrow for every share currently short. Borrowing costs have barely moved, at 0.56%. The lending market tells a story of a position that is unwinding at its own pace rather than being forced out. Options positioning remains calm: the put/call ratio of 0.54 is only a third of a standard deviation above its 20-day average of 0.53, and nowhere near the 52-week peak of 4.19 set earlier in the year.

The Street's picture is harder to read cleanly given stale coverage. The most recent analyst action of note was Lake Street raising its target to $289 in August 2025, still below where the stock traded through much of this year before the recent slide. The mean price target of $355 sits roughly 27% above the current price, though that figure reflects a consensus that has not been updated recently and should be treated with caution. Raymond James initiated at Market Perform in early 2025 without a target, and KeyBanc's Sector Weight initiation from early 2024 adds a neutral voice to the register. Factor scores are mixed: EPS surprise ranks in the 67th percentile, a solid beat record. The short score rank of 5 and days-to-cover rank of 7 both reflect how heavily scrutinised the name is relative to peers. Earnings yield ranks at the 59th percentile, reasonable but not cheap at a trailing price-to-earnings of around 18.

The ownership picture carries a few points worth noting. Neuberger Berman crossed the 5% threshold and filed a 13G in July, lifting its stake from 4.5% to 6.9%. Wasatch Advisors, by contrast, trimmed from 8.8% to 7.1% in its most recent October filing. BlackRock added modestly in the September quarter to reach 14.7% of shares. T. Rowe Price added roughly 111,000 shares in the same period. The insider register, meanwhile, has been net negative: the 90-day net across recent Form 4 filings shows sales of roughly $12.9 million, led by Executive Chairman R. Jeffrey Bailly, who sold around $4.1 million of stock in August. Those sales were not disclosed as being under a 10b5-1 plan, which makes them more notable than routine scheduled disposals. No insiders filed purchases in the same window.

Wikipedia page traffic offers a footnote worth flagging. The Wikimedia Foundation data shows retail attention running at a z-score of 3.1 against the company's own 90-day history, a meaningfully elevated reading as of October 19. That dataset carries no measured relationship to UFPT's financials and cannot be called a leading indicator, but the spike in attention is consistent with the Q3 earnings period drawing more eyes to the name than usual.

With Q3 now in the books and the next scheduled earnings event not until late February 2027, the focus shifts to whether the ongoing short interest retreat continues at the current pace or stalls if the results disappoint. The gap between the current price and where the bulk of covering analysts have their targets set is the other thread to watch.